Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The extract is administered under the tongue, providing repeated low‑dose exposure to grass pollen proteins. This exposure gradually shifts the immune system from an IgE‑driven allergic response toward a protective IgG4 response and activates regulatory T‑cells, fostering long‑term tolerance to the allergen.

The dosing schedule for Oralair is individualized by the prescribing clinician. Typically, a titration phase is followed by a maintenance dose, but the exact regimen, including the number of tablets and duration, must be set by the healthcare professional based on the patient’s age, severity of allergy, and response to therapy.

Safety data for Oralair in pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Oralair product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and the necessary import documentation.

Oralair is a sublingual tablet, offering a non‑injectable alternative to subcutaneous allergen immunotherapy (SCIT). It can be self‑administered at home after the initial supervised dose, which may improve convenience and adherence. However, SCIT may be preferred for certain allergens or when a faster desensitisation is required.

Oralair tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not refrigerate or freeze the product. Keep the tablets out of reach of children and avoid exposing them to excessive heat.

The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing water. The patient should keep the tablet in place for several minutes, as instructed by the prescriber, to ensure optimal absorption through the sublingual mucosa.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe oral or facial swelling that can compromise breathing, and respiratory distress or bronchospasm. Patients should be educated to recognize early signs of these reactions and seek immediate medical attention if they occur.

Oralair is contraindicated in individuals with a known hypersensitivity to any component of the tablet, those with severe uncontrolled asthma, or patients who have experienced a severe systemic reaction to a previous grass pollen immunotherapy. It should also be avoided in patients taking medications that significantly increase the risk of anaphylaxis without appropriate medical supervision.